Affordable Access

deepdyve-link
Publisher Website

Residual C-peptide secretion and hypoglycemia awareness in people with type 1 diabetes

Authors
  • Wellens, Martine J1
  • Vollenbrock, Charlotte E1
  • Dekker, Pim2
  • Boesten, Lianne S M3
  • Geelhoed-Duijvestijn, Petronella H4
  • de Vries-Velraeds, Martine M C2
  • Nefs, Giesje2
  • Wolffenbuttel, Bruce H R1
  • Aanstoot, Henk-Jan2
  • van Dijk, Peter R1
  • 1 University of Groningen, University Medical Center Groningen, Groningen, Netherlands , Groningen (Netherlands)
  • 2 Diabeter, Center for Paediatric and Adolescent Diabetes Care and Research, Rotterdam, The Netherlands , Rotterdam
  • 3 IJsselland Hospital, Capelle aan den IJssel, Netherlands , Capelle aan den IJssel (Netherlands)
  • 4 Medical Centre Haaglanden, Den Haag, The Netherlands , Den Haag
Type
Published Article
Journal
BMJ Open Diabetes Research & Care
Publisher
BMJ
Publication Date
Sep 15, 2021
Volume
9
Issue
1
Identifiers
DOI: 10.1136/bmjdrc-2021-002288
PMID: 34526306
PMCID: PMC8444236
Source
PubMed Central
Keywords
Disciplines
  • 1506
  • 1869
License
Unknown

Abstract

Introduction This study aimed to assess the association between fasting serum C-peptide levels and the presence of impaired awareness of hypoglycemia (IAH) in people with type 1 diabetes. Research design and methods We performed a cross-sectional study among 509 individuals with type 1 diabetes (diabetes duration 5–65 years). Extensive clinical data and fasting serum C-peptide concentrations were collected and related to the presence or absence of IAH, which was evaluated using the validated Dutch version of the Clarke questionnaire. A multivariable logistic regression model was constructed to investigate the association of C-peptide and other clinical variables with IAH. Results In 129 (25%) individuals, residual C-peptide secretion was detected, while 75 (15%) individuals reported IAH. The median (IQR) C-peptide concentration among all participants was 0.0 (0.0–3.9) pmol/L. The prevalence of severe hypoglycemia was lower in people with demonstrable C-peptide versus those with absent C-peptide (30% vs 41%, p=0.025). Individuals with IAH were older, had longer diabetes duration, more frequently had macrovascular and microvascular complications, and more often used antihypertensive drugs, antiplatelet agents and cholesterol-lowering medication. There was a strong association between IAH and having a severe hypoglycemia in the preceding year. In multivariable regression analysis, residual C-peptide, either continuously or dichotomous, was associated with lower prevalence of IAH (p=0.040–0.042), while age at diabetes onset (p=0.001), presence of microvascular complications (p=0.003) and body mass index (BMI) (p=0.003) were also independently associated with the presence of IAH. Conclusions Higher BMI, the presence of microvascular complications and higher age at diabetes onset were independent risk factors for IAH in people with type 1 diabetes, while residual C-peptide secretion was associated with lower risk of this complication.

Report this publication

Statistics

Seen <100 times